Advanced in Peripheral T-Cell Lymphoma

Dr. Youn H. Kim

Dermatology
Lymphoma Program
875 Blake Wilbur Drive, 
Palo Alto, CA 
 (1546.3 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Peripheral T-Cell Lymphoma
Lymphoma Program
875 Blake Wilbur Drive, 
Palo Alto, CA 
 (1546.3 mi)
OverviewInsuranceLocationsClinical Research

Overview

Youn Kim is a Dermatologist in Palo Alto, California. Dr. Kim and is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome.

Her clinical research consists of co-authoring 146 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 2 clinical trials in the study of Peripheral T-Cell Lymphoma.

Graduate Institution
Stanford University School Of Medicine
Specialties
Dermatology
Licenses
Dermatology in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

Lymphoma Program
875 Blake Wilbur Drive, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Enrollment Status: Recruiting
Publish Date: October 02, 2024
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Other, Biological
Study Drugs: Interferon Gamma-1b, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

146 Total Publications

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.
Journal: The Journal of dermatological treatment
Published: February 02, 2025
Similar Doctors
Experienced in Peripheral T-Cell Lymphoma
Dr. Bernice Y. Kwong
Dermatology
Experienced in Peripheral T-Cell Lymphoma
Dr. Bernice Y. Kwong
Dermatology

General Dermatology Clinic At Hoover Pavilion

211 Quarry Rd, 
Palo Alto, CA 
 (0.6 mi)
650-723-6855
Languages Spoken:
English
Offers Telehealth

Bernice Kwong is a Dermatologist in Palo Alto, California. Dr. Kwong and is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Hartsfield Syndrome, Eschar, Graft Versus Host Disease (GvHD), and Acute Febrile Neutrophilic Dermatosis.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile